Reproduced with permission from Wolters Kluwer Health; Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38; Wiviott SD et al. Circulation 2008;118:1626–1636.
The editors would like to thank the many members of the American Diabetes Association 71st Scientific Sessions presenting faculty who generously gave their time to ensure the accuracy and quality of the articles in this publication.